(Q86507881)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

New agents for bacillus Calmette-Guérin-refractory bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Jennifer J Ahn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

James M McKiernan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

5 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

219-232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

Management of stage T1 tumors of the bladder: International Consensus Panel.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Intravesical therapy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

New drugs and new approaches for the treatment of metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Taxol and taxotere in bladder cancer: in vitro activity and urine stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Albumin-bound paclitaxel: a next-generation taxane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agentsThe ONCOFID-P® paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.008

10.1016/J.UCL.2013.01.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540780%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference